The Department of Health made the submission, supported the evaluation, waived related cost recovery fees for itself, attended the PBAC meetings at which it has been considered and presumably participated in the discussion, wrote the outcome and managed the listing process. How is this not deeply problematic? …
A deeply problematic situation caused by officials making it up as they go
July 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Queensland to host AusBiotech International Conference and sector leadership strengthened with director re-election
October 24, 2025 - - Australian Biotech -
David Henderson to Lead Takeda’s Specialty Franchise in Oceania
October 24, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 24, 2025 - - BioPharma -
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News